share_log

东曜药业-B公布中期业绩 实现营收3.28亿元同比增长80%

Dongyao Pharmaceutical-B announced interim results and achieved revenue of 328 million yuan, an 80% year-on-year increase

新浪港股 ·  Aug 13, 2023 19:54

Dongyao Pharmaceutical-B (01875) announced its 2023 interim results. Operating revenue was RMB 328 million (same unit), an increase of 80% over the previous year. Excluding the impact of one-time licensing revenue for the first half of 2022, revenue increased 147% year-on-year. Among them, product sales revenue was about 278 million yuan, an increase of 167% over the previous year, mainly from the core product bevacizumab injection, the sales volume of paxindine, which continues to rise. CDMO/CMO business revenue reached RMB 46.546 million, up 105% year on year. New projects are expected to contribute more revenue to the group in the second half of the year. The Group's cash flow and hematopoietic capacity continued to increase, and the net cash flow from operating activities continued to be positive, up 116% year on year to 62.413 million yuan.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment